Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney

  • Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care

    Diabetes Research and Clinical Practice Date published:

  • Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

    European Journal of Heart Failure Date published:

  • Authors' Reply: Dialysate Sodium and Mortality: 140 mmol/L at Hemodialysis Initiation by Default?

    Journal of the American Society of Nephrology Date published:

  • Authors' Reply: Dialysate Sodium and Mortality: One Size Does Not Fit All

    Journal of the American Society of Nephrology Date published:

  • IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

    Nature Medicine Date published:

  • Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From Four Large-Scale Placebo-Controlled Outcome Trials

    Circulation Date published:

  • Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS)

    American Journal of Respiratory and Critical Care Medicine Date published:

  • #1657 Impact of cumulative fluid and sodium imbalance exposure on cause-specific mortality in hemodialysis

    Nephrology Dialysis Transplantation Date published:

  • Applications of SGLT2 inhibitors beyond glycaemic control

    Nature Reviews Nephrology Date published:

  • Effects of SGLT2 inhibitors on cause-specific cardiovascular death in patients with chronic kidney disease: a meta-analysis of CKD progression trials

    Clinical Journal of the American Society of Nephrology Date published:

  • Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids

    Arthritis & Rheumatology Date published:

  • Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

    Circulation Date published:

  • WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN

    Kidney International Reports Date published:

  • The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy

    Kidney International Reports Date published:

  • Not enough known about fenofibrate’s kidney effects in people with Type 2 diabetes

    Diabetes Research and Clinical Practice Date published:

  • Capacity for the management of kidney failure in the International Society of Nephrology Oceania and South East Asia (OSEA) region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)

    Kidney International Supplements Date published: